🧾 What This Document Is

This is a Definitive Proxy Statement (DEF 14A) for Solid Biosciences Inc. (SLDB). Think of it as the official "agenda packet" for the company's annual shareholder meeting. Its purpose is to give shareholders the information they need to vote on key company matters remotely. This meeting is scheduled for June 10, 2026, and will be held entirely online.

👉 Why it matters: As a shareholder, this document tells you what you're being asked to vote on, who is running the company, how much they get paid, and asks for your approval on major governance decisions.

🏢 What The Company Does

In simple terms, Solid Biosciences is a biotech company focused on developing gene therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder. Their work is highly specialized and in the research and development stage, meaning they are creating potential future treatments but likely have products that are not yet generating significant revenue.

🗳️ The Proposals You're Voting On

Shareholders are being asked to vote on five main items:

Elect Three Directors: Re-elect Clare Kahn, Adam Stone, and Lynne Sullivan to the board.
Ratify a Director Appointment: Approve (in an advisory, non-binding way) the board's decision to move co-founder Ilan Ganot to a different director class.
Ratify the Auditor: Re-appoint PricewaterhouseCoopers LLP as the company's independent accounting firm for 2026.
Increase Authorized Shares: Approve ampering the company's charter to double the number of allowed common shares from 240 million to 480 million.
Approve Executive Compensation: Cast an advisory, non-binding vote on the pay for top executives.

👉 The board recommends voting "FOR" all five proposals.

👥 Board of Directors & Governance

The board is structured into three classes with staggered terms. Here’s a snapshot:

Class II (Up for Election): Clare Kahn (regulatory expert), Adam Stone (biotech investor), Lynne Sullivan (financial expert).
Class I (Term until 2028): Alexander Cumbo (CEO), Ilan Ganot (Co-Founder), Sukumar Nagendran (R&D leader).
Class III (Term until 2027): Martin Freed, Georgia Keresty, Ian Smith (Executive Chairman).

The board believes in separating the CEO and Chairman roles, which they say enhances oversight. Most directors are considered independent, except for the CEO. The company has standard governance practices, including a clawback policy to recover executive pay if financial results are later restated.

💰 Executive Compensation

The filing details the pay for the top executives, including the CEO. The compensation committee, advised by an independent consultant, sets pay based on biotech industry benchmarks. The details of specific salaries, bonuses, and stock awards are contained within the full statement.

👉 This is a "Say-on-Pay" vote. It's your chance to give a non-binding opinion on whether executive pay is reasonable.

📦 Why the Authorized Shares Proposal is a Big Deal

Proposal #4 is asking to create 240 million new shares (for a total of 480 million). Companies usually do this to have shares available for future needs like:

Raising money through stock offerings.
Acquiring other companies.
Issuing employee stock options.

👉 What this signals: While common, increasing the authorized share count can lead to dilution, meaning your percentage ownership of the company could decrease if these new shares are issued. The board needs this flexibility for strategic moves.

📅 Key Logistics

Record Date: You must have been a shareholder by April 16, 2026, to vote.
How to Vote: You can vote online (www.proxyvote.com), by phone (1-800-690-6903), by mail, or during the virtual meeting.
Virtual Meeting: Attended online at http://www.virtualshareholdermeeting.com/SLDB2026 on June 10, 2026, at 8:00 a.m. ET.

⚖️ Big Picture: Strengths (👍) & Risks (⚠️)

👍 Strengths:
- Experienced Board: Directors have deep roots in biotech, finance, and regulation.
- Clear Focus: Dedicated to a serious, niche disease (DMD), which can be a path to approval if trials succeed.
- Governance Structures: Has standard committees (audit, comp, etc.) and policies like a clawback.
⚠️ Risks:
- Pre-Revenue Biotech: As a development-stage company, it burns cash and its success hinges on clinical trial outcomes.
- Dilution Risk: The proposal to double authorized shares could dilute current shareholders if used.
- Operational Challenges: Gene therapy is complex and expensive to develop and manufacture.

🧠 The Analogy

Think of this filing as the annual "shareholder town hall" notice. The company leadership is saying: "Here's who we are, here's what we did with your investment last year, here's our plan, and here are the specific decisions we need your vote on to keep operating and growing. Some are routine, and one (the share increase) gives us more tools for the future, but you need to trust us to use them wisely."

🧩 Final Takeaway

This proxy statement is primarily about continuity and flexibility. It seeks to re-elect the existing board, approve the auditor, and give an advisory nod to executive pay. The most consequential item is the request to double the authorized shares, which is a standard but important move to ensure the company has the financial tools for future deals, funding, or incentives as it develops its gene therapies.

SLDB Seeks Shareholder Approval to Double Authorized Shares